富瀚微(300613.SZ):董事龔虹嘉涉嫌信披違法違規 被中證監立案調查
格隆匯11月13日丨富瀚微(300613.SZ)公佈,2019年11月13日,公司收到董事龔虹嘉的通知,龔虹嘉收到中國證監會《調查通知書》(編號:稽總調查字191304號):因涉嫌信息披露違法違規,中國證監會根據《中華人民共和國證券法》的有關規定,對龔虹嘉進行立案調查。
此次立案調查事項系針對龔虹嘉個人的調查,不會影響其在公司的正常履職,公司生產經營活動亦不受影響。被立案調查的事件是涉及當事人為海康威視核心經營層設計實施的股權激勵方案,與公司和公司其他董高監無關。調查期間,龔虹嘉及相關各方將積極配合中國證監會的調查工作,並嚴格按照監管要求履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.